RenovaCare (RCAR) POS AM 20 May 15 2015 Q1 Prospectus update (post-effective amendment) Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015
Document And Entity Information
Entity Registrant Name	Renovacare, Inc.
Entity Central Index Key	1016708
Document Type	POS AM
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$370,646	$683,098	$1,508,843
Prepaid expenses	35,209	7,448	1,230
Total current assets	405,855	690,546	1,510,073
Note receivable from Duke Mountain			80,000
Intangible Assets	152,854	162,854	162,854
Total assets	558,709	853,400	1,752,927
Current liabilities
Accounts payable and accrued expense	62,759	6,182	11,222
Accounts payable and accrued expenses - related parties	19,615	7,255	44,219
Contract and contribution payable	87,500	187,500
Total current liabilities	169,874	200,937	55,441
Contract and contribution payable	168,750	178,125
Total liabilities	338,624	379,062	55,441
STOCKHOLDERS' EQUITY
Preferred stock: $0.0001 par value: Authorized: 10,000,000 shares, Issued and outstanding: nil
Common stock: $0.00001 par value: Authorized: 500,000,000 shares, issued and outstanding: 66,575,122 shares	666	666	666
Additional paid-in capital	8,139,804	8,128,860	7,220,612
Accumulated deficit	-7,920,385	-7,655,188	-5,523,792
Total stockholders' equity	220,085	474,338	1,697,486
Total liabilities and stockholders' equity	$558,709	$853,400	$1,752,927

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
STOCKHOLDERS' EQUITY
Preferred stock, par value	$0.00	$0.00	$0.00
Preferred stock, Authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares Issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value	$0.00	$0.00	$0.00
Common stock, Authorized	500,000,000	500,000,000	500,000,000
Common stock, shares Issued	66,575,122	66,575,122	66,575,122
Common stock, shares outstanding	66,575,122	66,575,122	66,575,122

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Consolidated Statements Of Operations
Revenue
Expenses
Research and development expenses	61,390		975,667
General and administrative expenses	203,807	268,021	1,155,729	628,545
Total operating expenses	265,197	268,021	2,131,396	628,545
Loss from continuing operations			-2,131,396	-628,545
Discontinued operations
Gain on disposal of assets (oil and gas)				49,338
Loss on disposal of subsidiary (Fostung)				-453,581
Loss on discontinued operations				-404,243
Net loss	($265,197)	($268,021)	($2,131,396)	($1,032,788)
Loss per common share	$0	$0	($0.03)	($0.02)
Loss per common share continuing operations			($0.03)	($0.01)
Loss per common share discontinued operations			$0	($0.01)
Weighted average shares outstanding	66,575,122	66,575,122	66,575,122	63,401,149

CONSOLIDATED_STATEMENT_COMPREH

CONSOLIDATED STATEMENT COMPREHENSIVE LOSS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Consolidated Statement Comprehensive Loss
Net loss	($2,131,396)	($1,032,788)
Other comprehensive loss
Reclassification adjustment on disposal of subsidiary		4,104
Total comprehensive loss	($2,131,396)	($1,028,684)

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Common Stock	Additional Paid-In Capital	Accumulated deficit	Accumulated other comprehensive (loss)	Total
Beginning Balance, Amount at Dec. 31, 2012	$631	$5,462,236	($4,491,004)	($4,104)	$967,759
Beginning Balance, Shares at Dec. 31, 2012	63,075,122
Stock based compensation - Series A Warrant		237,971			237,971
Stock based compensation - options		15,440			15,440
Issuance of Units, shares	3,500,000
Issuance of Units, Value	35	1,504,965			1,505,000
Reclassification adjustment on disposal of subsidiary				4,104	4,104
Net Loss			-1,032,788		-1,032,788
Ending Balance, Amount at Dec. 31, 2013	666	7,220,612	-5,523,792		1,697,486
Ending Balance, Shares at Dec. 31, 2013	66,575,122
Stock based compensation - Series A Warrant		848,388			848,388
Stock based compensation - options		59,860			59,860
Reclassification adjustment on disposal of subsidiary
Net Loss			-2,131,396		-2,131,396
Ending Balance, Amount at Dec. 31, 2014	$666	$8,128,860	($7,655,188)		$474,338
Ending Balance, Shares at Dec. 31, 2014	66,575,122

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net loss	($265,197)	($268,021)	($2,131,396)	($1,032,788)
Adjustments to reconcile net loss to net cash flows from operating activities:
Impairment loss	10,000
Stock based compensation expense	10,944	6,782	59,860	15,440
Stock based consulting expense		126,833	848,388	237,971
Gain on disposal of oil and gas properties				-49,338
Loss on disposal of subsidiary				453,581
Bad debt expense			80,000
Changes in operating assets and liabilities:
Decrease (increase) in receivables		-800		800
Decrease (increase) in prepaid expenses	-27,761	-32,006	-6,218	6,332
(Decrease) increase in accounts payable and accrued expenses	56,577	7,635	-42,004	18,104
(Decrease) increase in accounts payable and accrued expenses - related party	12,360
(Decrease) increase in contract and contributions payable	-109,375		365,625
Net cash flows from operating activities	-312,452	-159,577	-825,745	-349,898
Cash flows from investing activities:
Proceeds from disposal of oil and gas properties				3,000
Acquisition of intellectual property				-162,854
Net cash flows from investing activities				-159,854
Cash flows from financing activities:
Sale of common stock and warrants				1,505,000
Net cash flows from financing activities				1,505,000
Change in cash and cash equivalents	-312,452	-159,577	825,745	995,248
Cash and cash equivalents, beginning of period	683,098	1,508,843	1,508,843	513,595
Cash and cash equivalents, end of period	370,646	1,349,266	683,098	1,508,843
Supplemental disclosure of cash flow information:
Non-cash investing and financing activities - Note received on disposal of subsidiary				$80,000

Organization_Nature_and_Contin

Organization, Nature and Continuance of Operations	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Notes to Financial Statements
Note 1. Organization, Nature and Continuance of Operations	RenovaCare, Inc., together with its wholly owned subsidiary (the “Company”), focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications. The Company was previously involved in the exploration and development of both mineral exploration properties and oil and gas properties.	RenovaCare, Inc., together with its wholly owned subsidiary (the “Company”), focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications. The Company was previously involved in the exploration and development of both mineral exploration properties and oil and gas properties. The Company sold its oil and gas properties on February 18 and 19, 2013 and sold its subsidiary which controlled various mineral leases and mining claims on December 31, 2013.
	On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp. (“RenovaCare Sciences”), completed the acquisition of its flagship technology, a treatment methodology for skin isolation, spraying and associated equipment for the regeneration of human skin cells (the “Cell Deposition Device”), along with the associated United States patent applications and two (2) foreign patents, the first of which expires on August 22, 2027 and the second of which expires on April 26, 2031.	On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences Corp. (“RenovaCare Sciences”), a Nevada corporation formerly known as Janus Acquisition Corp., entered into an asset purchase agreement with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach’s rights, title and interest to a treatment methodology for skin isolation , spraying and associated equipment for the regeneration of human skin cells (the “Cell Deposition Device”), along with the associated US and foreign patents and patent applications. The development of the Cell Deposition Device is in the early stages and we anticipate that significant time and financial resources will be required to further develop the technology and determine whether a commercially viable product can be developed.
	The Company has recently incurred net operating losses and operating cash flow deficits. As of March 31, 2015, the Company’s total accumulated deficit is $7.9 million. The Company does not currently generate revenues and will continue to incur losses from operations and operating cash flow deficits in the future. Management believes that the Company’s cash and cash equivalent balances, anticipated cash flows from operations and other external sources of capital will be sufficient to meet the Company’s cash requirements through December 31, 2015. The future of the Company after December 31, 2015 will depend in large part on its ability to successfully raise capital from external sources to fund operations and, or, generate revenue and cash flow from operations.	On December 31, 2013, we entered into a stock purchase agreement with Duke Mountain Resources, Inc. (“Duke”), a Nevada corporation, pursuant to which we sold to Duke 100% of the issued and outstanding shares of Fostung Resources Ltd. (“Fostung Resources”), a corporation organized under the laws of Ontario, Canada and a wholly owned subsidiary of ours, for a promissory note in the amount of $80,000, which amount approximated the fair value of the leases and mining claims controlled by Fostung Resources, as concluded by an independent third-party geological consultant. During 2014 management determined that collection of any portion of the principal outstanding under the promissory note from Duke was no longer probable. As a result, the Company wrote off the balance of principal due under the note amounting to $83,200, including interest receivable of $3,200, during the year ended December 31, 2014.
		The Company has recently incurred net operating losses and operating cash flow deficits. The Company’s total accumulated deficit is $7.7 million as of December 31, 2014. The Company does not currently generate revenues and will continue to incur losses from operations and operating cash flow deficits in the future. Management believes that the Company’s cash and cash equivalent balances, anticipated cash flows from operations and other external sources of capital will be sufficient to meet our cash requirements through December 31, 2015. The future of the Company after December 2015 will depend in large part on its ability to successfully raise capital from external sources to fund operations.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Notes to Financial Statements
Note 2. Significant Accounting Policies	Basis of Presentation and Principles of Accounting	Basis of Presentation and Principles of Accounting
	The interim consolidated financial statements included herein have been prepared by the Company, without audit, in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) pursuant to Part 210 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations, although the Company believes that the disclosures included are adequate to make the information presented not misleading.	As the Company is devoting substantially all of its efforts to establishing a new business, and while planned principal operations have commenced, there has been no revenue generated from sales, license fees or royalties, and as such, the Company is considered a development stage company. Accordingly, the Company’s consolidated financial statements are presented in accordance with authoritative accounting guidance related to a development stage enterprise.
	In management’s opinion, the unaudited consolidated financial statements contained herein reflect all adjustments, consisting solely of normal recurring items, which are necessary for the fair presentation of the Company’s financial position, results of operations, and cash flows on a basis consistent with that of the Company’s prior audited consolidated financial statements. The Company has evaluated information about subsequent events that became available to us through the date the financial statements were issued. This information relates to events, transactions or changes in circumstances that would require us to adjust the amounts reported in the financial statements or to disclose information about those events, transactions or changes in circumstances. The results of operations for interim periods may not be indicative of results to be expected for the full fiscal year. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements, including the notes thereto for the year ended December 31, 2014, which may be found under the Company’s profile on EDGAR.	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Topic 915): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which states that in connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). The adoption of this update did not have a material effect on the Company’s financial statements.
	Principles of Consolidation	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company adopted ASU 2014-10 during the quarter ended June 30, 2014, thereby no longer presenting or disclosing any information required by Topic 915.
	These consolidated financial statements have been prepared in accordance with US GAAP and include the accounts of the Company and its wholly owned subsidiary, RenovaCare Sciences. All significant intercompany transactions and balances have been eliminated. RenovaCare Sciences was incorporated under the laws of the State of Nevada on June 12, 2013.	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605, Revenue Recognition. The new revenue recognition standard requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for interim and annual reporting periods beginning after December 15, 2016 and is to be applied retrospectively. The Company does not currently have any revenue. As such, ASU 2014-09 will not have any effect on the Company’s results of operations and financial position. If the Company begins generating revenue prior to the effective date of ASU 2014-09, it will evaluate the effect that ASU 2014-09 will have on its results of operations and financial position.
	Applicable Accounting Guidance	Principles of Consolidation
	Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board’s Accounting Standards Codification.	These consolidated financial statements have been prepared in accordance with US GAAP and include the accounts of the Company and its wholly owned subsidiary, RenovaCare Sciences. All significant intercompany transactions and balances have been eliminated. RenovaCare Sciences was incorporated under the laws of the State of Nevada on June 12, 2013.
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605, Revenue Recognition. The new revenue recognition standard requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for interim and annual reporting periods beginning after December 15, 2016 and is to be applied retrospectively. The Company does not currently have any revenue. As such, ASU 2014-09 will not have any effect on the Company’s results of operations and financial position. If the Company begins generating revenue prior to the effective date of ASU 2014-09, it will evaluate the effect that ASU 2014-09 will have on its results of operations and financial position. At its April 1, 2015, meeting, the FASB agreed to propose a one-year deferral of the revenue recognition standard’s effective date for all entities. The FASB intends to issue and exposure draft in the near term with a 30-day comment period.	Applicable Accounting Guidance
	Accounting Estimates	Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board’s Accounting Standards Codification.
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results, as determined by future events, may differ from these estimates.	Accounting Estimates
	Cash and Cash Equivalents	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results, as determined by future events, may differ from these estimates.
	The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed federally insured limits.	Cash and Cash Equivalents
	Fair Value of Financial Instruments	The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed federally insured limits.
	The carrying amounts for cash and cash equivalents and payables approximate fair value based on observable quoted prices for active markets – Level 1 inputs.	Note Receivable from Duke Mountain
	Research and Development Costs	The note receivable from Duke Mountain is unsecured, bears interest at 4.0%, and principal and interest are due on December 31, 2015. During 2014 management determined that collection of any portion of the principal outstanding under the promissory note from Duke was no longer probable. As a result, the Company wrote off the balance due under the note amounting to $83,200, including interest receivable of $3,200, during the year ended December 31, 2014.
	The Company intends to outsource its research and development efforts and expense related costs as incurred, including the cost of manufacturing product for testing, licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual property acquired will be capitalized as it relates to particular research and development projects that may have alternative future uses.	Fair Value of Financial Instruments
	Intangible Assets	The carrying amounts for cash and cash equivalents, and payables approximate fair value based on observable quoted prices for active markets – Level 1 inputs.
	The intangible asset consists primarily of Cell Deposition Device technology that the Company acquired during 2013 and is recorded at cost. At the time of acquisition the technology had not reached technological feasibility. The amount capitalized is accounted for as an indefinite-lived intangible asset, subject to impairment testing until completion or abandonment. Upon successful completion, a determination will be made as to the then useful life of the intangible asset, generally determined by the period in which substantially all of the cash flows are expected to be generated, and begin amortization. The Company tests the intangible asset for impairment at least annually or more frequently if impairment indicators exist after performing a qualitative analysis. Management has multiple criteria that it considers when performing the qualitative analysis. The results of this review are then weighed and prioritized. If the totality of the relevant events and circumstances indicate that the intangible asset is not impaired, additional impairment tests are not necessary.	Research and Development Costs
	The Company assessed the following qualitative factors that could affect any change in the fair value of the intangible asset: analysis of the technology’s current phase, additional testing necessary to bring the technology to market, development of competing products, changes in projections caused by delays, changes in regulations, changes in the market for the technology and changes in cost projections to bring the technology to market. Based on a qualitative assessment, management concluded that a positive assertion can be made from the qualitative assessment that it is more likely than not that the intangible asset related to the Cell Deposition Device is not impaired. The Company did, however, determine that an intangible asset related to wound care technology, acquired during 2013, was impaired during the period ended March 31, 2015 and recorded an impairment loss (a component of research and development expenses) amounting to $10,000 which was equal to the amount capitalized.	The Company intends to outsource its research and development efforts and expense related costs as incurred, including the cost of manufacturing product for testing, licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual property acquired will be capitalized as it relates to particular research and development projects that may have alternative future uses.
	Stock Options	Intangible Assets
	The Company measures all stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes pricing model to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes pricing model requires management to make assumptions regarding option lives, expected volatility, and risk free interest rates.	The intangible asset consists primarily of Cell Deposition Device technology that the Company acquired during 2013 and is recorded at cost. At the time of acquisition, the technology had not reached technological feasibility. The amount capitalized is accounted for as an indefinite-lived intangible asset, subject to impairment testing until completion or abandonment. Upon successful completion, a determination will be made as to the then useful life of the intangible asset, generally determined by the period in which substantially all of the cash flows are expected to be generated, and begin amortization. The Company tests the intangible asset for impairment at least annually or more frequently if impairment indicators exist after performing a qualitative analysis. Management has multiple criteria that it considers when performing the qualitative analysis. The results of this review are then weighed and prioritized. If the totality of the relevant events and circumstances indicate that the intangible asset is not impaired, additional impairment tests are not necessary.
	Income Taxes	The Company assessed the following qualitative factors that could affect any change in the fair value of the intangible asset: analysis of the technology’s current phase, additional testing necessary to bring the technology to market, development of competing products, changes in projections caused by delays, changes in regulations, changes in the market for the technology and changes in cost projections to bring the technology to market. Based on a qualitative assessment, management concluded that a positive assertion can be made from the qualitative assessment that it is more likely than not that the intangible asset is not impaired.
	The Company recognizes income taxes on an accrual basis based on tax positions taken, or expected to be taken, in tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, the Company’s policy is to classify interest and penalties related to tax positions as interest expense. Since the Company’s inception, no such interest or penalties have been incurred. The Company did not record an income tax provision during the periods presented due to net taxable losses.	Stock Options
	Earnings (Loss) Per Share	The Company measures all stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes pricing model to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes pricing model requires management to make assumptions regarding option lives, expected volatility, and risk free interest rates.
	The Company presents both basic and diluted earnings per share (“EPS”) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. Potentially dilutive shares of common stock consisted of warrants to purchase shares of common stock (8,200,000 shares as of both March 31, 2015 and December 31, 2014) and options to purchase shares of common stock (185,000 shares as of both March 31, 2015 and December 31, 2014). During the periods presented, potentially dilutive shares of common stock were not included in the computation of dilutive loss per share as to do so would be anti-dilutive.	Income Taxes
	Related Party Transactions	The Company recognizes income taxes on an accrual basis based on tax positions taken, or expected to be taken, in tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. No provision for income taxes was recorded during the periods presented because the Company had a net taxable loss. Should they occur, our policy is to classify interest and penalties related to tax positions as interest expense. Since our inception, no such interest or penalties have been incurred.
	A related party is generally defined as (i) any person who holds 10% or more of the Company’s securities and their immediate families; (ii) the Company’s management; (iii) someone who directly or indirectly controls, is controlled by or is under common control with the Company; or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. See “Note 6. Related Party Transactions,” for further discussion.	Discontinued Operations
		The assets and financial results of the Company’s oil and gas and mineral assets are being reported as discontinued operations as a result of the sale of the oil and gas properties in February 2013 and the sale of the Company’s subsidiary which controlled various mineral leases and claims in December 2013. Certain amounts reported in the prior periods presented have been reclassified to conform to the current period financial statement presentation. These reclassifications have no effect on previously reported net income (loss). See “Note 3. Discontinued Operations” for a summary of the amounts reclassified for the periods presented herein.
		Earnings (Loss) Per Share
		The Company presents both basic and diluted earnings per share (“EPS”) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. Potentially dilutive shares of common stock consisted of warrants to purchase shares of common stock (8,200,000 shares for 2014 and 2013) and options to purchase shares of common stock (185,000 shares for 2014 and 80,000 shares for 2013). During the periods presented, potentially dilutive shares of common stock were not included in the computation of dilutive loss per share as to do so would be anti-dilutive.
		Comprehensive Income (Loss)
		Comprehensive loss is comprised of net loss, and a reclassification on disposal of subsidiary for the periods presented.
		Related Party Transactions
		A related party is generally defined as (i) any person who holds 10% or more of the Company’s securities and their immediate families; (ii) the Company’s management; (iii) someone who directly or indirectly controls, is controlled by or is under common control with the Company; or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. See “Note 7. Related Party Transactions,” for further discussion.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Note 3. Discontinued Operations	On February 18 and 19, 2013, we completed the sale and assignment of our working interests in our oil wells. Consideration for the sale and assignment was $3,000 cash. The carrying amount of the oil and gas properties was $24,127 on the date of disposal. The related asset retirement obligation amounted to $57,532 and liabilities assumed amounted to $12,932. Including the $3,000 cash received, the Company recognized a gain of $49,338 in the year ended December 31, 2013, as a result of the disposal.
	On December 31, 2013, we entered into a stock purchase agreement with Duke, pursuant to which we sold to Duke 100% of the issued and outstanding shares of Fostung Resources, a wholly owned subsidiary of ours, for a promissory note in the amount of $80,000, which amount approximated the fair value of the leases and mining claims controlled by Fostung Resources, as concluded by an independent third-party geological consultant. Principal and interest at 4.0% are payable on December 31, 2015. Including the $80,000 of consideration received, the Company recognized a loss on the disposal of the subsidiary of $453,581. On December 31, 2014, we determined that it was unlikely that we would collect the principal and interest due on the promissory note from Duke and wrote off the outstanding balance of both the note and the interest receivable.
	The Company reported no revenue in discontinued operations for the years ended December 31, 2014 and December 31, 2013. The Company’s net loss reported in discontinued operations for the years ended December 31, 2014 and December 31, 2013 were $0 and $(404,243), respectively. The Company has not recognized any revenue nor incurred expenses with respect to its previously owned oil and gas and mineral assets since their respective sales, and will not recognize any continuing cash flows with respect to these properties in the future.

Intangible_Assets_Intellectual

Intangible Assets - Intellectual Property	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Notes to Financial Statements
Note 4. Intangible Assets - Intellectual Property	On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an asset purchase agreement with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach’s rights, title and interest in the Cell Deposition Device. The Company plans to further the development of the Cell Deposition Device and, if commercially viable, bring the product to market. Acquisition related costs amounted to $52,852 and were capitalized together with the cash payment upon the closing of the transaction in July 2013 of $100,002. Additional costs capitalized during 2013, and which related to an option to evaluate a wound cap technology, amounted to $10,000. The Company allowed this option to expire, and during the period ended March 31, 2015 recorded an impairment loss amounting to $10,000, which was equal to the amount capitalized. Intangible assets amounted to $152,854 and $162,854 at March 31, 2015 and December 31, 2014, respectively.	On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an asset purchase agreement with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach’s rights, title and interest in the Cell Deposition Device. The Company plans to further the development of the Cell Deposition Device, if commercially viable, bring the product to market. Acquisition related costs amounted to $52,852 and were capitalized together with the cash payment in 2013 of $100,002. Additional costs capitalized during 2013, and which related to a wound cap technology, amounted to $10,000. At December 31, 2014 and 2013, intangible assets amounted to $162,854.
	The asset purchase agreement was amended on September 9, 2014 (the “Amended APA”). Pursuant to the terms of the Amended APA, an additional $300,000 will be paid in four installments: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. The Company paid the first installment of $100,000 in January 2015. At March 31, 2015, $50,000 of the amount payable to Dr. Gerlach was recorded as other current liabilities and $150,000 was recorded as other long term liabilities in the accompanying consolidated balance sheet.	This asset purchase agreement was amended on September 9, 2014 (the “Amended APA”). Pursuant to the terms of the Amended APA, upon the closing of the transaction in July 2013, the Company paid Dr. Gerlach $100,002. An additional $300,000 will be paid in four installments: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. The Company paid the first installment of $100,000 in January 2015. At December 31, 2014, $150,000 of the amount payable to Dr. Gerlach was recorded as current liabilities and $150,000 was recorded as long term liabilities in the accompanying consolidated balance sheet.
	As further consideration for the Cell Deposition Device, the Company issued to Dr. Gerlach a Series A Stock Purchase Warrant (the “Series A Warrant”) entitling him to purchase 1,200,000 shares (each a “Warrant Share”) of the Company’s common stock at an exercise price of $0.35 per share. Pursuant to the terms of the Amended APA, the Series A Warrant will vest in five equal installments of 240,000 shares on each of July 12, 2014, July 12, 2015, July 12, 2016, July 12, 2017 and July 12, 2018. Vesting will no longer be contingent on the achievement of certain milestones and on Dr. Gerlach’s continuing to provide consulting services to the Company, but instead on passage of time. Prior to September 9, 2014, the effective date of the Amended APA, the value of the Series A Warrant was recognized as consulting expenses over the vesting term. Effective September 9, 2014, the Company measured and expensed the value of the Series A Warrant in full and recorded this value as research and development costs. The fair value of each Warrant Share as of September 9, 2014, using the Black-Scholes option pricing model, was $0.91.	As further consideration for the Cell Deposition Device, the Company issued to Dr. Gerlach a Series A Stock Purchase Warrant (the “Series A Warrant”) entitling him to purchase 1,200,000 shares (each a “Warrant Share”) of the Company’s common stock at an exercise price of $0.35 per share. Pursuant to the terms of the Amended APA, the Series A Warrant will now vest in five equal installments of 240,000 shares on each of July 12, 2014, July 12, 2015, July 12, 2016, July 12, 2017 and July 12, 2018. Vesting will no longer be contingent on the achievement of certain milestones and on Dr. Gerlach’s continuing to provide consulting services to the Company, but instead on the passage of time. Prior to September 9, 2014, the effective date of the Amended APA, the value of the Series A Warrant was recognized as consulting expenses over the vesting term. In addition, the fair value of each Warrant Share was estimated at the end of each reporting period during which Dr. Gerlach rendered services using the Black-Scholes option pricing model. Effective September 9, 2014, the Company measured and expensed the value of the Series A Warrant in full and recorded this value as research and development costs. The fair value of each Warrant Share as of September 9, 2014, using the Black-Scholes option pricing model, was $0.91.
	Consulting expense associated with the Series A Warrant amounted to $0 during the three months ended March 31, 2015 (2014: $126,833). There were no research and development expense associated with the Series A Warrant during the three months ended March 31, 2015 and March 31, 2014.	Assumptions required for the Black-Scholes model are as follows:
	See also “Note 7. Subsequent Events.”		2014
		Risk-free interest rate		1.72	%
		Expected life in years		4.75
		Expected Volatility		93.8	%
		Expected dividend yield		0	%
		Consulting expense associated with the Series A Warrant amounted to $311,173 and $237,971 during the years ended December 31, 2014 and 2013, respectively. Research and development costs associated with the Series A Warrant amounted to $537,215 and $nil in the years ended December 31, 2014 and 2013, respectively.

Common_Stock_Options

Common Stock Options	3 Months Ended									12 Months Ended
	Mar. 31, 2015									Dec. 31, 2014
Notes to Financial Statements
Note 5. Common Stock Options	Approval of the 2013 Long-Term Incentive Plan									Approval of the 2013 Long-Term Incentive Plan
	On June 20, 2013, the Board of Directors (the “Board”) adopted, subject to receiving shareholder approval, the 2013 Long-Term Incentive Plan (the “Incentive Plan”). The Incentive Plan provides for the issuance of stock options of up to 20,000,000 shares (subject to adjustment) of the Company’s common stock to officers, directors, key employees and consultants of the Company. Options granted to employees under the Incentive Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the Incentive Plan are limited to non-qualified stock options. On November 15, 2013, shareholders owning a majority of the Company’s issued and outstanding shares approved the Incentive Plan.									On June 20, 2013, the Board of Directors (the “Board”) adopted, subject to receiving shareholder approval, the 2013 Long-Term Incentive Plan (the “Incentive Plan”). The Incentive Plan provides for the issuance of stock options of up to 20,000,000 shares (subject to adjustment) of the Company’s common stock to officers, directors, key employees and consultants of the Company. Options granted to employees under the Incentive Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the Incentive Plan are limited to non-qualified stock options.
	The Incentive Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the Incentive Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted in any of the Company’s fiscal year, options to purchase more than 2,000,000 shares under the Incentive Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the Incentive Plan are exercisable no later than ten years after the date of grant.									The Incentive Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the Incentive Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted in any of the Company’s fiscal year, options to purchase more than 2,000,000 shares under the Incentive Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the Incentive Plan are exercisable no later than ten years after the date of grant.
	The exercise price per share of common stock for options granted under the Incentive Plan will be the fair market value of the Company’s common stock on the date of grant, using the closing price of the Company’s common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company’s common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the Incentive Plan after June 20, 2023.									The exercise price per share of common stock for options granted under the Incentive Plan will be the fair market value of the Company’s common stock on the date of grant, using the closing price of the Company’s common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company’s common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the Incentive Plan after June 20, 2023.
	As of March 31, 2015, there were 19,815,000 shares available for grant.									As of December 31, 2014, there were 19,815,000 shares available for grant.
	Stock Option Activity									Stock Option Activity
	The following table summarizes stock option activity for the period ended March 31, 2015:									On August 1, 2013, the Company granted to Messrs. Kirkland and Sierchio (20,000 stock options each) for stock options granted on August 1, 2013. The exercise price per share is $0.65; 10,000 options vested on the grant date and, subject to continued service as a member of our Board, the remaining 10,000 options vested on August 1, 2014. The Options Shares may be exercised on a “cashless basis” using the formula contained therein.
						Weighted				Effective December 1, 2013, we appointed Mr. Bold as our President & CEO and entered into an at-will consulting agreement (the “Consulting Agreement”) with Mr. Bold. Pursuant to the terms of the Consulting Agreement, Mr. Bold is expected to serve on a part-time basis and will receive an annual fee of $50,000, payable in 12 equal installments, which is prorated for any partial months during the term of the Consulting Agreement. In addition to Mr. Bold’s fee, he was issued a stock option to purchase up to 40,000 shares of our common stock at a price of $0.75 per share, the closing price of our common stock as quoted on the OTCQB on November 29, 2013. The shares may be exercised on a “cashless basis” using the formula contained therein and, subject to Mr. Bold’s continued service as our President and Chief Executive Officer, vest as follows: (a) 20,000 shares vested on December 1, 2014; and (b) 20,000 shares vest on December 1, 2015.
						Average
				Weighted		Remaining		Aggregate		On April 1, 2014, the Company appointed Ms. Patsy Trisler as its Vice President – Clinical & Regulatory Affairs and entered into an at-will consulting agreement (the “Trisler Consulting Agreement”) with Ms. Trisler. Pursuant to the terms of the Trisler Consulting Agreement, Ms. Trisler was issued an option to purchase up to 50,000 shares of the Company’s common stock at a price of $1.05 per share, the closing price of the Company’s common stock as quoted on the OTCQB on April 1, 2014. The shares may be exercised on a “cashless basis” using the formula contained therein and, subject to Ms. Trisler’s continued service as the Company’s Vice President – Clinical & Regulatory Affairs, the shares vest as follows, 10,000 on: (a) April 1, 2015; (b) April 1, 2016; (c) April 1, 2017; (d) April 1, 2018; and (e) April 1, 2019.
		Options		Average		Contractual		Intrinsic
		Outstanding		Exercise Price		Life (Years)		Value		On April 20, 2014, the Company appointed Andrew Danielson as its Director of Business Development and issued Mr. Danielson a stock option to purchase 5,000 shares of the Company’s common stock at a price of $1.05 per share, the closing price of the Company’s common stock as quoted on the OTCQB on April 17, 2014. The shares may be exercised on a “cashless basis” using the formula contained therein and, subject to Mr. Danielson’s continued service with the Company, vest on April 20, 2015.
	Balance January 1, 2015		185,000	$	0.83		9.12	$	9,300
	Options granted		-		_		-	$	0	On August 14, 2014, the Company granted to each of Messrs. Kirkland and Sierchio a stock option to purchase 20,000 shares of the Company’s common stock. The exercise price per share is $0.80; 10,000 options vested on the grant date and, subject to continued service as a member of the Company’s Board, the remaining 10,000 options vest on August 14, 2015 and may be exercised on a “cashless basis” using the formula contained therein.
	Balance March 31, 2015		185,000	$	0.83		8.87	$	110,800
	Exercisable at March 31, 2015		85,000	$	0.72		8.96	$	22,500	On August 14, 2014, the Company granted to Ms. Rhonda Rosen, the Company’s Chief Financial Officer, a stock option to purchase 10,000 shares of the Company’s common stock. The exercise price per share is $0.80; 5,000 options vested on the grant date and, subject to her continued service as an executive of the Company, the remaining 5,000 options vest on August 14, 2015 and may be exercised on a “cashless basis” using the formula contained therein.
	The fair value of stock options are estimated at the date of grant using the Black-Scholes option pricing model. There were no stock options granted during the three months ended March 31, 2015.									The following table summarizes stock option activity for the year ended December 31, 2014.
	During the three months ended March 31, 2015, stock-based compensation expense of $10,944 was recognized as general and administrative expenses. During the three months ended March 31, 2014, stock-based compensation expense of $6,782 was recognized as general and administrative expenses. There were 85,000 stock options vested and 100,000 stock options unvested as of March 31, 2015. As of March 31, 2015, the Company had $32,016 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized by April 1, 2019.															Weighted Average Remaining Contractual Life (Years)
	The Company issues new shares when options are exercised.													Weighted Average Exercise Price				Aggregate Intrinsic Value
												Options Outstanding
										Balance January 1, 2014			80,000	$	0.7		8.75	$	24,800
										Options granted			105,000	$	0.93		9.41	$	1,500
										Balance December 31, 2014			185,000	$	0.83		9.12	$	9,300
										Exercisable at December 31, 2014			85,000	$	0.72		8.97	$	7,850
										The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted during 2013 was approximately $0.49 to $0.57 per share. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company’s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award’s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:
											2014		2013
										Risk-free interest rate	1.58 – 1.62%		1.43 – 1.49%
										Expected life in years	5.5		5.5
										Weighted Avg Expected Volatility	94.4% - 105.3%		99.5 – 103.4%
										Expected dividend yield	0%		0%
										During the years ended December 31, 2014 and 2013, stock-based compensation expense of $59,860 and $15,440, respectively, was recognized as general and administrative expenses. There were 85,000 stock options vested and 100,000 unvested, as of December 31, 2014. As of December 31, 2014, the Company had $42,959 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized by December 31, 2019.
										The following table summarizes information about stock options outstanding and exercisable under our stock incentive plan at December 31, 2014:
												Number Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price
										$0.50 to $1.00			130,000		9.07	$	0.74		85,000		8.96	$	0.72
										$1.01 to $1.50			55,000		9.25		1.05		0		-		-
													185,000		9.12		0.83		85,000		8.96		0.72
										The Company issues new shares when options are exercised.

Commitments

Commitments	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Notes to Financial Statements
Note 6. Commitments	On August 1, 2013, the Company engaged Vector to assist the Company with identifying subject matter experts in the medical device and biotechnology industries and to assist the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology (collectively, the “Services”). In consideration of the Services, the Company will pay Vector a monthly consulting fee of $5,000.	On August 1, 2013, the Company engaged Vector to assist the Company with identifying subject matter experts in the medical device and biotechnology industries and to assist the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology (collectively, the “Services”). In consideration of the Services, the Company will pay Vector a monthly consulting fee of $5,000. The consulting agreement with Vector continues until December 31, 2014, unless earlier terminated by either party upon five days prior written notice. The Company has verbally agreed to continue paying Vector a monthly consulting fee of $5,000 in 2015.
	In connection with the Company’s anticipated Section 510(k) submission of its proprietary Cell Deposition Device to the Food and Drug Administration, the Company has engaged StemCell System GmbH (“StemCell Systems”) to provide it with prototypes and related documents. Pursuant to this engagement the Company incurred expenses of $44,910 in the three months ended March 31, 2015. The remaining payments are due prior to June 30, 2015, the exact amount and timing of which is dependent on the actual work performed.	In connection with the Company’s anticipated Section 510(k) submission of its proprietary Cell Deposition Device to the Food and Drug Administration, in June 2014 the Company engaged StemCell System GmbH (“StemCell Systems”) to provide it with prototypes and related documents. Pursuant to this engagement, the Company incurred expenses of $137,508 in the year ended December 31, 2014.
	On September 25, 2014, the Company entered into a Charitable Grant Agreement with the University of Pittsburgh (the “University”), pursuant to which the Company committed to provide a charitable donation to the University in the aggregate amount of $75,000 (the “Grant”). The Company will pay the Grant in eight quarterly installments of $9,375, with the first payment made on or before October 2014 and the final payment to be made on or before July 31, 2016. Dr. Gerlach, from whom the Company purchased the Cell Deposition Device, is a professor at the University. At March 31, 2015, $37,500 of the amount payable to the University was recorded as other current liabilities and $18,750 was recorded as other long term liabilities in the accompanying consolidated balance sheet.	On September 25, 2014, the Company entered into a Charitable Grant Agreement with the University of Pittsburgh (the “University”), pursuant to which the Company committed to provide a charitable donation to the University in the aggregate amount of $75,000 (the “Grant”). The Company will pay the Grant in eight quarterly installments of $9,375, with the first payment made on or before October 2014 and the final payment to be made on or before July 31, 2016. Dr. Gerlach, from whom the Company purchased the Cell Deposition Device, is a professor at the University. At December 31, 2014, $37,500 of the amount payable to the University was recorded as current liabilities and $28,125 was recorded as long term liabilities in the accompanying consolidated balance sheet.
	See also “Note 6. Related Party Transactions.”	See also “Note 7. Related Party Transactions.”

Related_Party_Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Notes to Financial Statements
Note 7. Related Party Transactions	As compensation for their service on the Board, Dr. Kirkland and Mr. Sierchio will receive an annual retainer of $6,000, payable in equal yearly installments in arrears and prorated for any partial years of service.	As compensation for their service on the Board, Dr. Kirkland and Mr. Sierchio will receive an annual retainer of $6,000, payable in equal yearly installments in arrears and prorated for any partial years of service. Additionally, on August 14, 2014, the Company granted to each of Dr. Kirkland and Mr. Sierchio an incentive stock option to purchase up to 20,000 shares of the Company’s common stock at an exercise price of $0.80 per share, the closing price of the Company’s common stock as quoted on the OTC Markets Group Inc. QB tier (the “OTCQB”) on the day prior to the grant. Subject to their continued service as a member of the Board, 10,000 of the shares vested immediately and 10,000 of the shares vested on the first anniversary of date of grant and may be exercised on a “cashless basis” using the formula contained therein.
	For the three months ended March 31, 2015, directors’ and consulting fees with respect to officers and directors of the Company were $6,000 (2014: $75,084). Legal fees incurred with respect to one of the Company’s directors in the three months ended March 31, 2015 were $38,980 (2014: $47,193). Amounts included in accounts payable and accrued expenses, and due to related parties, at March 31, 2015 were $19,615 and $7,255 as of December 31, 2014.	Effective September 30, 2013, Ms. Rosen resigned as President and Chief Executive Officer and the Company entered into an At-Will Executive Services Agreement (the “Rosen Services Agreement”), pursuant to which Ms. Rosen will serve as the Company’s Chief Financial Officer. Pursuant to the Rosen Services Agreement, Ms. Rosen will provide the Company with services consistent with that of a Chief Financial Officer on a part-time basis, for which she will be paid a monthly fee of $2,400 and will be reimbursed for any business related expenses. The Rosen Services Agreement is terminable by either the Company or Ms. Rosen upon advance written notice. On August 14, 2014, the Company granted to Ms. Rhonda Rosen, the Company’s Chief Financial Officer, 10,000 stock options. The exercise price per share is $0.80; 5,000 options vested on the grant date and, subject to her continued service as an executive of the Company, the remaining 5,000 options will vest on August 14, 2015 and may be exercised on a “cashless basis” using the formula contained therein.
		On November 29, 2013, the Company entered into a subscription agreement with Kalen Capital Corporation (the “Investor”), a private Alberta corporation wholly owned by Mr. Harmel S. Rayat and a majority shareholder of the Company’s, pursuant to which the Investor purchased 3,500,000 Units at a purchase price of $0.43 per Unit, for an aggregate purchase amount of $1,505,000. Each Unit consists of: (a) one share of common stock; (b) one Series B Warrant exercisable for one share of Common Stock at an exercise price of $0.43 per share if exercised within the first eighteen months or $0.46 per share if exercised after the first eighteen months and prior to expiration on November 29, 2018; and (c) one Series C Warrant exercisable for one share of common stock at an exercise price of $0.43 per share if exercised within the first eighteen months or $0.49 per share if exercised after the first eighteen months and prior to expiration on November 29, 2018. Each of the Series B Warrant and Series C Warrant contains a provision allowing the holder to exercise the respective warrant on a cashless basis as further set forth therein. The Unit price of $0.43 represents a 30% discount to the 20 day average closing price of the Common Stock as quoted on the OTCQB as of October 31, 2013, the last trading date prior to us entering into a non-binding term sheet with the Investor regarding the purchase of the Units.
		On December 1, 2013, the Company appointed Mr. Bold as its President & CEO and entered into the Consulting Agreement with Mr. Bold. Pursuant to the terms of the Consulting Agreement, Mr. Bold is expected to serve on a part-time basis and will receive an annual fee of $50,000, payable in 12 equal installments, which is prorated for any partial months during the term of the Consulting Agreement. In addition to Mr. Bold’s fee, he was issued an option to purchase up to 40,000 shares of the Company’s common stock at a price of $0.75 per share the closing price of the Company’s common stock as quoted on the OTCQB on November 29, 2013. The shares may be exercised on a “cashless basis” using the formula contained therein and, subject to Mr. Bold’s continued service as the Company’s President and Chief Executive Officer, 20,000 shares vested on December 1, 2014 and 20,000 shares will vest on December 1, 2015.
		On December 31, 2013, the Company completed the sale of 100% of the issued and outstanding shares of Fostung Resources to Duke for a promissory note in the amount of $80,000, which amount approximated the fair value of the leases and mining claims controlled by Fostung Resources, as concluded by an independent third-party geological consultant. Principal and interest at 4.0% are payable on December 31, 2015. Mr. Herdev S. Rayat, the majority shareholder of Duke, is the brother of Mr. Harmel S. Rayat, the Company’s majority shareholder. On December 31, 2014, we determined that it was unlikely that we would collect the principal and interest due on the promissory note from Duke and wrote off the outstanding balance of both the note and the interest receivable.
		On April 1, 2014, the Company appointed Ms. Patsy Trisler as its Vice President – Clinical & Regulatory Affairs and entered into the Trisler Consulting Agreement with Ms. Trisler. Pursuant to the terms of the Trisler Consulting Agreement, Ms. Trisler will receive a monthly fee of $5,000, which covers her services for up to 40 hours in any given month and will pay her an hourly fee of $125 for every hour in excess of forty, prorated for any partial hour. The Consulting Agreement may be terminated at any time by either Ms. Trisler or the Company. In addition to Ms. Trisler’s fee, she was issued an option to purchase up to 50,000 shares of the Company’s common stock at a price of $1.05 per share, the closing price of the Company’s common stock as quoted on the OTCQB on March 31, 2014. The Options Shares may be exercised on a “cashless basis” using the formula contained therein and, subject to Ms. Trisler’s continued service as the Company’s Vice President – Clinical & Regulatory Affairs, vest as follows, 10,000 shares on: (a) April 1, 2015; (b) April 1, 2016; (c) April 1, 2017; (d) April 1, 2018; and (e) April 1, 2019.
		On April 20, 2014, the Company appointed Andrew Danielson as its Director of Business Development at an annual salary of $60,000. In addition, Mr. Danielson was issued an option to purchase 5,000 shares of the Company’s common stock at a price of $1.05 per share, the closing price of the Company’s common stock as quoted on the OTCQB on April 17, 2014. The shares may be exercised on a “cashless basis” using the formula contained therein and, subject to Mr. Danielson’s continued service with the Company; the shares vest on April 20, 2015.
		For the year ended December 31, 2014 directors’ and consulting fees incurred with respect to officers and directors of the Company were $168,175 (2013: $49,097). Legal fees incurred with respect to one of the Company’s directors in the year ended December 31, 2014 were $156,175 (2013: $165,591). Management fees paid or due to our officers were $0 in 2014 (2013: $30,567). Amounts included in accounts payable and accrued expenses, and due to related parties, at December 31, 2014 were $7,255 (2013: $44,219).

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Note 8. Income Taxes	There is no current or deferred tax expense for 2014 and 2013, due to the Company’s loss position. Realization of the future tax benefits related to the deferred tax assets is dependent on many factors, including the Company’s ability to generate taxable income within the net operating loss carryforward period. Management has considered these factors in reaching its conclusion as to the valuation allowance for financial reporting purposes and has recorded a full valuation allowance against the deferred tax asset. The income tax effect, utilizing a 34% income tax rate, of temporary differences comprising the deferred tax assets and deferred tax liabilities is a result of the following at December 31:
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	2,285,000		$	2,027,000
	Other		337,000			86,000
			2,622,000			2,113,000
	Valuation allowance		(2,622,000	)		(2,113,000	)
	Net deferred tax assets	$	-		$	-
	The 2014 increase in the valuation allowance was $509,000 (2013: $155,000).
	The Company has available net operating loss carryforwards of approximately $6,722,000 for tax purposes to offset future taxable income which expires commencing 2015 through to the year 2034. Pursuant to the Tax Reform Act of 1986, annual utilization of the Company’s net operating loss carryforwards may be limited if a cumulative change in ownership of more than 50% is deemed to occur within any three-year period. The tax years 2011 through 2014 remain open to examination by federal agencies and other jurisdictions in which it operates.
	A reconciliation between the statutory federal income tax rate (34%) and the effective rate of income tax expense for the years ended December 31 follows:
		2014			2013
	Statutory federal income tax rate		34	%		34	%
	Valuation allowance		(34	%)		(34	%)
			0	%		0	%

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Note 9. Subsequent Events	On May 1, 2015, the Company entered into a new option agreement (the “Option Agreement”) with Dr. Jorg Gerlach, pursuant to which the Company obtained a one year exclusive option to evaluate a wound cap technology (the “Technology”), for the purpose of determining whether the Company would like to purchase or license the Technology. Pursuant to the terms of the Option Agreement, the Company will pay Dr. Gerlach a non-refundable fee of $24,000, payable in four quarterly installments of $6,000, with the first installment due on May 1, 2015.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Significant Accounting Policies Policies
Basis of Presentation and Principles of Accounting	The interim consolidated financial statements included herein have been prepared by the Company, without audit, in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) pursuant to Part 210 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such SEC rules and regulations, although the Company believes that the disclosures included are adequate to make the information presented not misleading.	As the Company is devoting substantially all of its efforts to establishing a new business, and while planned principal operations have commenced, there has been no revenue generated from sales, license fees or royalties, and as such, the Company is considered a development stage company. Accordingly, the Company’s consolidated financial statements are presented in accordance with authoritative accounting guidance related to a development stage enterprise.
	In management’s opinion, the unaudited consolidated financial statements contained herein reflect all adjustments, consisting solely of normal recurring items, which are necessary for the fair presentation of the Company’s financial position, results of operations, and cash flows on a basis consistent with that of the Company’s prior audited consolidated financial statements. The Company has evaluated information about subsequent events that became available to us through the date the financial statements were issued. This information relates to events, transactions or changes in circumstances that would require us to adjust the amounts reported in the financial statements or to disclose information about those events, transactions or changes in circumstances. The results of operations for interim periods may not be indicative of results to be expected for the full fiscal year. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements, including the notes thereto for the year ended December 31, 2014, which may be found under the Company’s profile on EDGAR.	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Topic 915): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which states that in connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). The adoption of this update did not have a material effect on the Company’s financial statements.
		In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company adopted ASU 2014-10 during the quarter ended June 30, 2014, thereby no longer presenting or disclosing any information required by Topic 915.
		In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605, Revenue Recognition. The new revenue recognition standard requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for interim and annual reporting periods beginning after December 15, 2016 and is to be applied retrospectively. The Company does not currently have any revenue. As such, ASU 2014-09 will not have any effect on the Company’s results of operations and financial position. If the Company begins generating revenue prior to the effective date of ASU 2014-09, it will evaluate the effect that ASU 2014-09 will have on its results of operations and financial position.
Principles of Consolidation	These consolidated financial statements have been prepared in accordance with US GAAP and include the accounts of the Company and its wholly owned subsidiary, RenovaCare Sciences. All significant intercompany transactions and balances have been eliminated. RenovaCare Sciences was incorporated under the laws of the State of Nevada on June 12, 2013.	These consolidated financial statements have been prepared in accordance with US GAAP and include the accounts of the Company and its wholly owned subsidiary, RenovaCare Sciences. All significant intercompany transactions and balances have been eliminated. RenovaCare Sciences was incorporated under the laws of the State of Nevada on June 12, 2013.
Applicable Accounting Guidance	Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board’s Accounting Standards Codification.	Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board’s Accounting Standards Codification.
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605, Revenue Recognition. The new revenue recognition standard requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for interim and annual reporting periods beginning after December 15, 2016 and is to be applied retrospectively. The Company does not currently have any revenue. As such, ASU 2014-09 will not have any effect on the Company’s results of operations and financial position. If the Company begins generating revenue prior to the effective date of ASU 2014-09, it will evaluate the effect that ASU 2014-09 will have on its results of operations and financial position. At its April 1, 2015, meeting, the FASB agreed to propose a one-year deferral of the revenue recognition standard’s effective date for all entities. The FASB intends to issue and exposure draft in the near term with a 30-day comment period.
Accounting Estimates	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results, as determined by future events, may differ from these estimates.	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results, as determined by future events, may differ from these estimates.
Cash and Cash Equivalents	The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed federally insured limits.	The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed federally insured limits.
Note Receivable from Duke Mountain	-	The note receivable from Duke Mountain is unsecured, bears interest at 4.0%, and principal and interest are due on December 31, 2015. During 2014 management determined that collection of any portion of the principal outstanding under the promissory note from Duke was no longer probable. As a result, the Company wrote off the balance due under the note amounting to $83,200, including interest receivable of $3,200, during the year ended December 31, 2014.
Fair Value of Financial Instruments	The carrying amounts for cash and cash equivalents and payables approximate fair value based on observable quoted prices for active markets – Level 1 inputs.	The carrying amounts for cash and cash equivalents, and payables approximate fair value based on observable quoted prices for active markets – Level 1 inputs.
Research and Development Costs	The Company intends to outsource its research and development efforts and expense related costs as incurred, including the cost of manufacturing product for testing, licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual property acquired will be capitalized as it relates to particular research and development projects that may have alternative future uses.	The Company intends to outsource its research and development efforts and expense related costs as incurred, including the cost of manufacturing product for testing, licensing fees and costs associated with planning and conducting clinical trials. The value ascribed to patents and other intellectual property acquired will be capitalized as it relates to particular research and development projects that may have alternative future uses.
Intangible Assets	The intangible asset consists primarily of Cell Deposition Device technology that the Company acquired during 2013 and is recorded at cost. At the time of acquisition the technology had not reached technological feasibility. The amount capitalized is accounted for as an indefinite-lived intangible asset, subject to impairment testing until completion or abandonment. Upon successful completion, a determination will be made as to the then useful life of the intangible asset, generally determined by the period in which substantially all of the cash flows are expected to be generated, and begin amortization. The Company tests the intangible asset for impairment at least annually or more frequently if impairment indicators exist after performing a qualitative analysis. Management has multiple criteria that it considers when performing the qualitative analysis. The results of this review are then weighed and prioritized. If the totality of the relevant events and circumstances indicate that the intangible asset is not impaired, additional impairment tests are not necessary.	The intangible asset consists primarily of Cell Deposition Device technology that the Company acquired during 2013 and is recorded at cost. At the time of acquisition, the technology had not reached technological feasibility. The amount capitalized is accounted for as an indefinite-lived intangible asset, subject to impairment testing until completion or abandonment. Upon successful completion, a determination will be made as to the then useful life of the intangible asset, generally determined by the period in which substantially all of the cash flows are expected to be generated, and begin amortization. The Company tests the intangible asset for impairment at least annually or more frequently if impairment indicators exist after performing a qualitative analysis. Management has multiple criteria that it considers when performing the qualitative analysis. The results of this review are then weighed and prioritized. If the totality of the relevant events and circumstances indicate that the intangible asset is not impaired, additional impairment tests are not necessary.
	The Company assessed the following qualitative factors that could affect any change in the fair value of the intangible asset: analysis of the technology’s current phase, additional testing necessary to bring the technology to market, development of competing products, changes in projections caused by delays, changes in regulations, changes in the market for the technology and changes in cost projections to bring the technology to market. Based on a qualitative assessment, management concluded that a positive assertion can be made from the qualitative assessment that it is more likely than not that the intangible asset related to the Cell Deposition Device is not impaired. The Company did, however, determine that an intangible asset related to wound care technology, acquired during 2013, was impaired during the period ended March 31, 2015 and recorded an impairment loss (a component of research and development expenses) amounting to $10,000 which was equal to the amount capitalized.	The Company assessed the following qualitative factors that could affect any change in the fair value of the intangible asset: analysis of the technology’s current phase, additional testing necessary to bring the technology to market, development of competing products, changes in projections caused by delays, changes in regulations, changes in the market for the technology and changes in cost projections to bring the technology to market. Based on a qualitative assessment, management concluded that a positive assertion can be made from the qualitative assessment that it is more likely than not that the intangible asset is not impaired.
Stock Options	The Company measures all stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes pricing model to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes pricing model requires management to make assumptions regarding option lives, expected volatility, and risk free interest rates.	The Company measures all stock-based compensation awards using a fair value method on the date of grant and recognizes such expense in its consolidated financial statements over the requisite service period. The Company uses the Black-Scholes pricing model to determine the fair value of stock-based compensation awards on the date of grant. The Black-Scholes pricing model requires management to make assumptions regarding option lives, expected volatility, and risk free interest rates.
Income Taxes	The Company recognizes income taxes on an accrual basis based on tax positions taken, or expected to be taken, in tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, the Company’s policy is to classify interest and penalties related to tax positions as interest expense. Since the Company’s inception, no such interest or penalties have been incurred. The Company did not record an income tax provision during the periods presented due to net taxable losses.	The Company recognizes income taxes on an accrual basis based on tax positions taken, or expected to be taken, in tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. No provision for income taxes was recorded during the periods presented because the Company had a net taxable loss. Should they occur, our policy is to classify interest and penalties related to tax positions as interest expense. Since our inception, no such interest or penalties have been incurred.
Earnings (Loss) Per Share	The Company presents both basic and diluted earnings per share (“EPS”) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. Potentially dilutive shares of common stock consisted of warrants to purchase shares of common stock (8,200,000 shares as of both March 31, 2015 and December 31, 2014) and options to purchase shares of common stock (185,000 shares as of both March 31, 2015 and December 31, 2014). During the periods presented, potentially dilutive shares of common stock were not included in the computation of dilutive loss per share as to do so would be anti-dilutive.	The Company presents both basic and diluted earnings per share (“EPS”) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. Potentially dilutive shares of common stock consisted of warrants to purchase shares of common stock (8,200,000 shares for 2014 and 2013) and options to purchase shares of common stock (185,000 shares for 2014 and 80,000 shares for 2013). During the periods presented, potentially dilutive shares of common stock were not included in the computation of dilutive loss per share as to do so would be anti-dilutive.
Comprehensive Income (Loss)	-	Comprehensive loss is comprised of net loss, and a reclassification on disposal of subsidiary for the periods presented.
Related Party Transactions	A related party is generally defined as (i) any person who holds 10% or more of the Company’s securities and their immediate families; (ii) the Company’s management; (iii) someone who directly or indirectly controls, is controlled by or is under common control with the Company; or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. See “Note 6. Related Party Transactions,” for further discussion.	A related party is generally defined as (i) any person who holds 10% or more of the Company’s securities and their immediate families; (ii) the Company’s management; (iii) someone who directly or indirectly controls, is controlled by or is under common control with the Company; or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. See “Note 7. Related Party Transactions,” for further discussion.

Intangible_Assets_Intellectual1

Intangible Assets - Intellectual Propert (Tables)	12 Months Ended
	Dec. 31, 2014
Intangible Assets - Intellectual Propert Tables
Assumptions required for the Black-Scholes model		2014	2013
	Risk-free interest rate	1.58 – 1.62%	1.43 – 1.49%
	Expected life in years	5.5	5.5
	Weighted Avg Expected Volatility	94.4% - 105.3%	99.5 – 103.4%
	Expected dividend yield	0%	0%

Common_Stock_Options_Tables

Common Stock Options (Tables)	3 Months Ended									12 Months Ended
	Mar. 31, 2015									Dec. 31, 2014
Common Stock Options Tables
Stock Option Activity	The following table summarizes stock option activity for the period ended March 31, 2015:															Weighted Average Remaining Contractual Life (Years)
						Weighted								Weighted Average Exercise Price				Aggregate Intrinsic Value
						Average						Options Outstanding
				Weighted		Remaining		Aggregate
		Options		Average		Contractual		Intrinsic		Balance January 1, 2014			80,000	$	0.7		8.75	$	24,800
		Outstanding		Exercise Price		Life (Years)		Value		Options granted			105,000	$	0.93		9.41	$	1,500
	Balance January 1, 2015		185,000	$	0.83		9.12	$	9,300	Balance December 31, 2014			185,000	$	0.83		9.12	$	9,300
	Options granted		-		_		-	$	0	Exercisable at December 31, 2014			85,000	$	0.72		8.97	$	7,850
	Balance March 31, 2015		185,000	$	0.83		8.87	$	110,800
	Exercisable at March 31, 2015		85,000	$	0.72		8.96	$	22,500
Assumptions required for the Black-Scholes model											2014		2013
										Risk-free interest rate	1.58 – 1.62%		1.43 – 1.49%
										Expected life in years	5.5		5.5
										Weighted Avg Expected Volatility	94.4% - 105.3%		99.5 – 103.4%
										Expected dividend yield	0%		0%
stock options outstanding												Number Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price
										$0.50 to $1.00			130,000		9.07	$	0.74		85,000		8.96	$	0.72
										$1.01 to $1.50			55,000		9.25		1.05		0		-		-
													185,000		9.12		0.83		85,000		8.96		0.72

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes Tables
Schedule of deferred tax assets and liabilities		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	2,285,000		$	2,027,000
	Other		337,000			86,000
			2,622,000			2,113,000
	Valuation allowance		(2,622,000	)		(2,113,000	)
	Net deferred tax assets	$	-		$	-
Reconciliation of the statutory federal income tax expense (benefit)	A reconciliation between the statutory federal income tax rate (34%) and the effective rate of income tax expense for the years ended December 31 follows:
		2014			2013
	Statutory federal income tax rate		34	%		34	%
	Valuation allowance		(34	%)		(34	%)
			0	%		0	%

Organization_Nature_and_Contin1

Organization Nature and Continuance of Operations (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Dec. 31, 2013
Organization Nature And Continuance Of Operations Details Narrative
Accumulated deficit	($7,655,188)	($7,920,385)	($5,523,792)
Principal under due amounting portion note	83,200
Interest Receivable	$3,200

Significant_Accounting_Policie2

Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015
Significant Accounting Policies Details Narrative
Common stock consisted of warrants to purchase shares	8,200,000	8,200,000
Options to purchase shares of common stock	185,000	185,000
Principal under due amounting portion note	$83,200
Interest Receivable	$3,200

Discontinued_Operations_Detail

Discontinued Operations (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Discontinued Operations Details Narrative
Carrying amount of the oil and gas properties		$24,127
Asset retirement obligation		57,532
Asset retirement obligation, liabilities assumed		12,932
Cash received		3,000
Recognized gain	49,338
Net loss reported	$0	($404,243)

Intangible_Assets_Intellectual2

Intangible Assets - Intellectual Propert (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Intangible Assets - Intellectual Propert Details
Weighted average risk-free interest rate	1.72%
Expected life in years	4 years 9 months
Weighted Avg Expected Volatility	93.80%
Expected dividend yield	$0

Intangible_Assets_Intellectual3

Intangible Assets - Intellectual Property (Details Narrative) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Impairment loss	$10,000
Intangible assets	152,854		162,854	162,854
Other current liabilities	37,500		37,500
Other long term liabilities	18,750		28,125
Consulting expense associated with the Series A Warrant amounted	0	126,833	237,971	311,173
Research and development costs associated with the Series A Warrant amounted	0	0	0	537,215
Dr Gerlach [Member]
Other current liabilities	50,000
Other long term liabilities	$150,000

Common_Stock_Options_Details

Common Stock Options (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Options Outstanding
Options outstanding - beginning balance	185,000	80,000
Options granted		105,000
Options oustanding - ending balance	185,000	185,000
Options exercisable	85,000	85,000
Weighted average exercise price
Options outstanding - beginning balance	$0.83	$0.70
Options granted		$0.93
Options outstanding - ending balance	$0.83	$0.83
Options exercisable	$0.72	$0.72
Weighted average remaining contracted term
Warrants outstanding - beginning balance	9 years 1 month 13 days	8 years 9 months
Options granted		9 years 4 months 28 days
Warrants outstanding - ending balance	8 years 10 months 13 days	9 years 1 month 13 days
Warrants exercisable	8 years 11 months 16 days	8 years 11 months 19 days
Aggregate intrinsic value
Options outstanding - beginning balance	$9,300	$24,800
Options granted	0	1,500
Options outstanding - ending balance	110,800	9,300
Options exercisable	$22,500	$7,850

Common_Stock_Options_Details_1

Common Stock Options (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Weighted average risk-free interest rate	1.72%
Expected life in years	4 years 9 months
Weighted Avg Expected Volatility	93.80%
Expected dividend yield	$0
Equity Option [Member]
Expected life in years	5 years 6 months	5 years 6 months
Expected dividend yield	$0	$0
Equity Option [Member] | Minimum
Weighted average risk-free interest rate	1.58%	1.43%
Weighted Avg Expected Volatility	94.40%	99.50%
Equity Option [Member] | Maximum
Weighted average risk-free interest rate	1.62%	1.49%
Weighted Avg Expected Volatility	105.30%	103.40%

Common_Stock_Options_Details_2

Common Stock Options (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Dec. 31, 2013
Number Outstanding	185,000
Weighted Average Remaining Contractual Life (Years)	9 years 1 month 13 days
Weighted Average Exercise Price	$0.83	$0.83	$0.70
Number Exercisable	85,000
Weighted Average Remaining Contractual Life (Years)	8 years 11 months 16 days
Weighted Average Exercise Price	0.72
$0.50 to $1.00 [Member]
Number Outstanding	130,000
Weighted Average Remaining Contractual Life (Years)	9 years 26 days
Weighted Average Exercise Price	$0.74
Number Exercisable	85,000
Weighted Average Remaining Contractual Life (Years)	8 years 11 months 16 days
Weighted Average Exercise Price	0.72
$1.01 to $1.50 [Member]
Number Outstanding	55,000
Weighted Average Remaining Contractual Life (Years)	9 years 3 months
Weighted Average Exercise Price	$1.05
Number Exercisable	0
Weighted Average Exercise Price

Common_Stock_Options_Details_N

Common Stock Options (Details Narrative) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Common Stock Options Details Narrative
Shares available for grant	19,815,000		19,815,000
Stock-based compensation administrative expense	$10,944	$6,782	$59,860	$15,440
Stock options vested	85,000		85,000
Stock options unvested	100,000		100,000
Unrecognized compensation cost	$32,016		$42,959

Commitments_Details_Narrative

Commitments (Details Narrative) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Commitments Details Narrative
Incurred expenses	$137,508	$137,508
Other current liabilities	37,500	37,500
Other long term liabilities	$18,750	$28,125

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Accounts payable - related parties	$19,615		$7,255	$44,219
Officers and Directors [Member] | Consulting fees [Member]
Fees paid or due to related party	6,000	75,084
Directors [Member] | Legal Fee [Member]
Fees paid or due to related party	38,980	47,193	156,175	165,591
Officer and directors [Member] | Consulting fees [Member]
Fees paid or due to related party			168,175	49,097
Officer and directors [Member] | Management Fee [Member]
Fees paid or due to related party			$0	$30,567

Income_Taxes_Details

Income Taxes (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforwards	$2,285,000	$2,027,000
Other	337,000	86,000
Deferred tax assets gross	2,622,000	2,113,000
Valuation allowance	-2,622,000	-2,113,000
Deferred tax asset

Income_Taxes_Details_1

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes Details 1
Statutory federal income tax rate	34.00%	34.00%
Change in valuation allowance	-34.00%	-34.00%
Income tax provision (benefit)	0.00%	0.00%

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes Details Narrative
Increase in the valuation allowance	$509,000	$155,000